PortfoliosLab logoPortfoliosLab logo
FMST vs. ORMP
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

FMST vs. ORMP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Foremost Lithium Resource & Technology Ltd. Common stock (FMST) and Oramed Pharmaceuticals Inc. (ORMP). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

FMST vs. ORMP - Yearly Performance Comparison


Fundamentals

EPS

FMST:

-$0.27

ORMP:

$1.03

Total Revenue (TTM)

FMST:

$0.00

ORMP:

$2.00M

Gross Profit (TTM)

FMST:

$0.00

ORMP:

-$79.00K

EBITDA (TTM)

FMST:

-$3.43M

ORMP:

$58.42M

Returns By Period

In the year-to-date period, FMST achieves a -16.98% return, which is significantly lower than ORMP's 27.97% return.


FMST

1D
6.02%
1M
-22.47%
YTD
-16.98%
6M
-39.73%
1Y
117.28%
3Y*
5Y*
10Y*

ORMP

1D
3.66%
1M
-0.44%
YTD
27.97%
6M
38.15%
1Y
70.42%
3Y*
18.71%
5Y*
-18.59%
10Y*
-6.63%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

FMST vs. ORMP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FMST
FMST Risk / Return Rank: 7272
Overall Rank
FMST Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
FMST Sortino Ratio Rank: 8181
Sortino Ratio Rank
FMST Omega Ratio Rank: 7373
Omega Ratio Rank
FMST Calmar Ratio Rank: 7272
Calmar Ratio Rank
FMST Martin Ratio Rank: 6464
Martin Ratio Rank

ORMP
ORMP Risk / Return Rank: 8383
Overall Rank
ORMP Sharpe Ratio Rank: 8484
Sharpe Ratio Rank
ORMP Sortino Ratio Rank: 8383
Sortino Ratio Rank
ORMP Omega Ratio Rank: 7777
Omega Ratio Rank
ORMP Calmar Ratio Rank: 8888
Calmar Ratio Rank
ORMP Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FMST vs. ORMP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Foremost Lithium Resource & Technology Ltd. Common stock (FMST) and Oramed Pharmaceuticals Inc. (ORMP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


FMSTORMPDifference

Sharpe ratio

Return per unit of total volatility

0.92

1.45

-0.54

Sortino ratio

Return per unit of downside risk

2.18

2.28

-0.10

Omega ratio

Gain probability vs. loss probability

1.23

1.26

-0.03

Calmar ratio

Return relative to maximum drawdown

1.54

3.44

-1.90

Martin ratio

Return relative to average drawdown

2.34

7.67

-5.33

FMST vs. ORMP - Sharpe Ratio Comparison

The current FMST Sharpe Ratio is 0.92, which is lower than the ORMP Sharpe Ratio of 1.45. The chart below compares the historical Sharpe Ratios of FMST and ORMP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


FMSTORMPDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.92

1.45

-0.54

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.23

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.09

Sharpe Ratio (All Time)

Calculated using the full available price history

0.22

-0.06

+0.29

Correlation

The correlation between FMST and ORMP is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

FMST vs. ORMP - Dividend Comparison

FMST has not paid dividends to shareholders, while ORMP's dividend yield for the trailing twelve months is around 7.35%.


Drawdowns

FMST vs. ORMP - Drawdown Comparison

The maximum FMST drawdown since its inception was -69.37%, smaller than the maximum ORMP drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for FMST and ORMP.


Loading graphics...

Drawdown Indicators


FMSTORMPDifference

Max Drawdown

Largest peak-to-trough decline

-69.37%

-94.25%

+24.88%

Max Drawdown (1Y)

Largest decline over 1 year

-69.37%

-18.89%

-50.48%

Max Drawdown (5Y)

Largest decline over 5 years

-94.25%

Max Drawdown (10Y)

Largest decline over 10 years

-94.25%

Current Drawdown

Current decline from peak

-67.53%

-87.74%

+20.21%

Average Drawdown

Average peak-to-trough decline

-43.34%

-70.62%

+27.28%

Ulcer Index

Depth and duration of drawdowns from previous peaks

45.75%

8.48%

+37.27%

Volatility

FMST vs. ORMP - Volatility Comparison

Foremost Lithium Resource & Technology Ltd. Common stock (FMST) has a higher volatility of 24.05% compared to Oramed Pharmaceuticals Inc. (ORMP) at 14.54%. This indicates that FMST's price experiences larger fluctuations and is considered to be riskier than ORMP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


FMSTORMPDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.05%

14.54%

+9.51%

Volatility (6M)

Calculated over the trailing 6-month period

70.49%

37.14%

+33.35%

Volatility (1Y)

Calculated over the trailing 1-year period

128.52%

48.81%

+79.71%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

126.96%

81.19%

+45.77%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

126.96%

72.78%

+54.18%

Financials

FMST vs. ORMP - Financials Comparison

This section allows you to compare key financial metrics between Foremost Lithium Resource & Technology Ltd. Common stock and Oramed Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00K1.00M1.50M2.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober00
(FMST) Total Revenue
(ORMP) Total Revenue
Values in USD except per share items